Daily Stock Highlights: Dow’s Record Run, S&P Gains, Nasdaq Dips, Plus Lilly, Tesla, Nvidia -( $AAPl $DIA $EPRX $LLY $MCD $MTWO $OPEN $SER $SPY Rise!)

In honor of Veterans Day, the market brought both rally and resilience, as portfolio generals weighed AI ambition against time-honored value plays. Whether saluting S&P records or commiserating with Nasdaq laggards, investors marched onward—sometimes in formation, sometimes in hopeful disorder, and always looking for the next bullish bugle. Indeed, Wall Street marked Veterans Day with a decidedly mixed salute to risk-taking—some blue chips boosted their berets, while the tech-heavy Nasdaq tripped over its shoelaces. Investors digested headline macro reports and more than a few market plot twists: from Nvidia’s sudden swoon to Tesla’s compensation fireworks. Here’s the market’s parade review—for posterity, profit, and just a dash of sophisticated humor.

Index Performances

The S&P 500 rallied 1.5% to close at 6,846.81, +.21% with eight of its eleven broad sectors saluting in the green after falling to 6,807.58 in the early going. The Dow Jones flexed its muscle, surging more than 500 points to a record close at 47,927.96, +1.18% and the Russell 2000 joined the festivities with a modest rise closing at 2,458.28,+.11% after dropping early. However, the Nasdaq tripped on its own AI ambitions, dragged lower by Nvidia’s stumble and profit-taking across tech’s usual suspects and closed at 23,468.30,-.25%.

Macroeconomic Data and Reports

Today’s calendar featured the ADP jobs data signaling a softer labor market—a notion that sent economists into a coffee-fueled huddle. The jobless claims 4-week average nudged down to 249,000, slightly below previous readings, while the Monthly Budget Statement revealed a robust $198 billion surplus, providing policymakers with a post-shutdown fiscal cushion.

Notable Company News & Stock Performances

Eli Lilly (LLY): Shares closed up another 2.27% at $988.62 following bullish R&D expansions in diabetes and oncology, strengthened by partnerships scaling up obesity medicine access and embracing AI-powered therapy development.
Nvidia: The chipmaker sank 2.96% to $193.16 after SoftBank disclosed a full exit, briefly chilling Wall Street’s recent obsession with all things silicon-driven. Despite this, Nvidia maintains a “Strong Buy” consensus among analysts looking past today’s noise to future dominance.
Apple (AAPL): Displayed textbook restraint in AI spending, outperforming peers as a port in the tech storm closing at $275.25, +2.16%. Its shares rose, the biggest point-gainer in the S&P today, with investors favoring its cash-rich, stress-free approach.
Tesla (TSLA): Closed down 1.26% at $439.62.
Broadcom (AVGO): Shares fell 1.79% to $351.96 after recently being propelled by its AI infrastructure pivot and blockbuster OpenAI collaboration, with earnings anticipated to provide further fireworks.
Meta: The social media titan stabilized at $627.08,-.74% after last month’s steep post-earnings tumble, as investors recalibrated their faith in Mark Zuckerberg’s Metaverse ambitions.
Nokia, McDonald’s (MCD, $306.83, +2.58%), Rio Tinto (RIO, $70.32,+.04%), Oracle, Intel, OKLO, Opendoor (OPEN, $8.48, +6.40%), Palantir Technologies: News flow was lighter today, but these names rode the broad equity tide with movements mostly in line with their sectors. Notably, McDonald’s.

Tariffs, FOMC, Yield Curve, and Rates

No new tariff salvos were fired today; investors remain on edge for future global chess moves. The yield curve held steady following the Senate’s shutdown-ending vote, with rates market watching for clues on the next Fed move. The 10-yr is at 4.121% and the 2-yr is at 3.601%. The Federal Reserve’s foggy data backdrop—thanks to government shutdown interruptions—means rate cuts for December are no longer a “foregone conclusion”; the next FOMC meeting is slated for December 9-10, with uncertainty as its co-host.

Commodities and Cryptocurrency Prices

Gold and Silver: Both metals shimmered, with gold holding just below $4,135.60/oz and silver showing strength as geopolitical risks percolated closing at $51.065/oz.
Oil: Prices rose 1.41% to $60.98/bbl rising on Russia sanctions.
Bitcoin: Fell sharply ~3% to the ~$103k level.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4896), a leader in innovative insulin delivery technology, announced (Nov. 3) the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.53, +4.82%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 4) its financial results for the third quarter of 2025 and provided a business update. Dr. James Helliwell, Chief Executive Officer of Eupraxia stated, “The compelling 52-week data from our RESOLVE trial reported this quarter further reinforce the potential of EP-104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE). Our highest-dose cohort delivered the largest improvements in tissue health outcomes and eosinophil reduction observed to date, with no additional safety concerns. Coupled with the successful completion of our $80.5 million financing supported by strong life-science focused investors, we are now well resourced to advance the EP-104GI program, including through topline data from the Phase 2b RESOLVE Trial expected in the third quarter of 2026.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4960), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that it will report its financial results for the quarter ended September 30, 2025, after the close of U.S. markets on Thursday, November 13, 2025. Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update.

Volato Group, Inc. (NYSE American: SOAR, $1.38) and M2i Global, Inc. (MTWO, 10, +8.58%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $4.08, +2.26%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s disease. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $37.22, +.92%) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

Index Performances

Macroeconomic Data and Reports

Notable Company News & Stock Performances

Tariffs, FOMC, Yield Curve, and Rates

Commodities and Cryptocurrency Prices

VP Watchlist Updates

The Sources

Related

You May Also Like

Can Centessa’s $250M Equity Windfall Transform Sleep Disorder Treatments? -( $CNTA $IBB $XBI )

U.S. Based GeoVax Labs Seeks To Challenge Bavarian Nordic’s Vaccine Monopoly Amid $3 Billion Buyout – ( $GOVX $BVNKF $IBB $XBI )

Your Guide To Staying Informed In The Markets